Ind-Swift Laboratories Limited Asset Resilience Ratio
Ind-Swift Laboratories Limited asset resilience ratio. Ind-Swift Laboratories Limited (INDSWFTLAB) has an Asset Resilience Ratio of 28.07% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See INDSWFTLAB defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Ind-Swift Laboratories Limited (2006–2025)
Asset resilience ratio of Ind-Swift Laboratories Limited from 2006 to 2025. This chart shows how Ind-Swift Laboratories Limited's Asset Resilience Ratio has changed over time. Read INDSWFTLAB total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Ind-Swift Laboratories Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see INDSWFTLAB current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs4.00 Billion | 25.89% |
| Short-term Investments | Rs335.31 Million | 2.17% |
| Total Liquid Assets | Rs4.33 Billion | 28.07% |
Asset Resilience Insights
- Very High Liquidity: Ind-Swift Laboratories Limited maintains exceptional liquid asset reserves at 28.07% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Ind-Swift Laboratories Limited Industry Peers by Asset Resilience Ratio
Compare Ind-Swift Laboratories Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Ind-Swift Laboratories Limited Asset Resilience Ratio by Year (2006–2025)
Ind-Swift Laboratories Limited asset resilience ratio by year from 2006 to 2025. The table below shows the annual Asset Resilience Ratio data for Ind-Swift Laboratories Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 2.74% | Rs393.66 Million ≈ $4.26 Million |
Rs14.38 Billion ≈ $155.55 Million |
+2.55pp |
| 2024-03-31 | 0.19% | Rs27.87 Million ≈ $301.43K |
Rs14.60 Billion ≈ $157.94 Million |
-0.08pp |
| 2023-03-31 | 0.27% | Rs49.55 Million ≈ $535.81K |
Rs18.24 Billion ≈ $197.27 Million |
-0.39pp |
| 2022-03-31 | 0.66% | Rs118.90 Million ≈ $1.29 Million |
Rs18.01 Billion ≈ $194.75 Million |
+0.20pp |
| 2021-03-31 | 0.46% | Rs83.02 Million ≈ $897.84K |
Rs18.18 Billion ≈ $196.66 Million |
-0.15pp |
| 2020-03-31 | 0.60% | Rs112.72 Million ≈ $1.22 Million |
Rs18.70 Billion ≈ $202.23 Million |
-0.33pp |
| 2019-03-31 | 0.93% | Rs178.74 Million ≈ $1.93 Million |
Rs19.24 Billion ≈ $208.07 Million |
+1.16pp |
| 2018-03-31 | -0.24% | Rs-47.69 Million ≈ $-515.75K |
Rs20.23 Billion ≈ $218.78 Million |
-1.61pp |
| 2017-03-31 | 1.37% | Rs293.79 Million ≈ $3.18 Million |
Rs21.38 Billion ≈ $231.16 Million |
+1.38pp |
| 2015-03-31 | -0.01% | Rs-2.15 Million ≈ $-23.21K |
Rs22.44 Billion ≈ $242.66 Million |
-0.01pp |
| 2013-03-31 | 0.00% | Rs1.00 Million ≈ $10.81K |
Rs23.74 Billion ≈ $256.75 Million |
-0.09pp |
| 2012-03-31 | 0.10% | Rs21.00 Million ≈ $227.11K |
Rs22.05 Billion ≈ $238.49 Million |
-1.64pp |
| 2011-03-31 | 1.73% | Rs301.00 Million ≈ $3.26 Million |
Rs17.39 Billion ≈ $188.03 Million |
+0.34pp |
| 2006-03-31 | 1.39% | Rs71.60 Million ≈ $774.31K |
Rs5.14 Billion ≈ $55.60 Million |
-- |
About Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hy… Read more